Renovaro Biosciences Inc (RENB) Stock
RENB is no longer traded. Renovaro Biosciences was delisted from the Nasdaq in September 2025.
Prices on this page are historical; the last trade was September 29, 2025 at $1.27.
Renovaro Biosciences stock price history
RENB final trading statistics
- Final close
- $1.27
- Final trading day
- Sep 29, 2025
- Market cap at delisting
- $29.35M
- Shares outstanding
- 23.18M
- Final 52-week range
- $0.13 – $2.10
- Avg. volume (final 3 mo.)
- 193,761
- All-time high (split-adj.)
- $125.50 · Nov 2021
- All-time low (split-adj.)
- $1.27 · Sep 2025
- Return since IPO
- -97.9%
- Beta
- 0.53
- Book value / share
- -$1.20
- Price / book
- -1.05
Renovaro Biosciences annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2025 | $0.00 | -$80.7M | -$7.93 |
| FY2024 | $0.00 | -$80.7M | -$1.85 |
| FY2023 | $0.00 | -$39.7M | -$6.82 |
| FY2022 | $0.00 | -$113.4M | -$17.47 |
| FY2021 | $0.00 | -$26.7M | -$0.56 |
Last five fiscal years reported before the delisting; fiscal year ending June. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Renovaro Biosciences Inc
Lunai Bioworks Inc., a pre-clinical stage biotechnology company, engages in the development of pharmaceutical and biological products for the treatment of cancer and HIV in the United States and the Netherlands. It operates through two segments, RENB and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops an artificial intelligence platform technology for early cancer detection and its recurrence that uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients. The company has a strategic collaboration with Nebul to advance the early detection of cancer and other diseases. The company was formerly known as Renovaro Inc. and changed its name to Lunai Bioworks Inc. in August 2025. Lunai Bioworks Inc. is headquartered in Los Angeles, California.
Renovaro Biosciences stock FAQ
What happened to Renovaro Biosciences stock?
Renovaro Biosciences stock was delisted from the Nasdaq. Its final close was $1.27 on September 29, 2025.
Is RENB stock still trading?
No. RENB was delisted from the Nasdaq in September 2025 and no longer trades on a U.S. exchange.
What was the last price of RENB stock?
RENB closed at $1.27 on its final trading day, September 29, 2025, for a market value of about $29.35M.
What were Renovaro Biosciences's revenue and earnings in its last full fiscal year?
Renovaro Biosciences reported revenue of $0.00 and net income of -$80.7M in fiscal 2025, its last full year as a public company.
When did Renovaro Biosciences go public?
Renovaro Biosciences Inc stock began trading on February 2, 2015.